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Drug discovery based on cellular phenotypes is
impeded by the challenge of identifying the molec-
ular target. To alleviate this problem, we developed
a chemical proteomic process to identify cellular
proteins that bind to small molecules. CB30865 is
a potent (subnanomolar) and selective cytotoxic
compound of previously unknown mechanism of
action. By combining chemical proteomics with
biochemical and cellular pharmacology we have
determined that CB30865 cytotoxicity is due to sub-
nanomolar inhibition of nicotinamide phosphoribo-
syltransferase (Nampt), an enzyme present in the
NAD biosynthetic pathway. Cancer cells develop
dependence on Nampt due to increased energy
requirements and the elevated activity of NAD con-
suming enzymes such as sirtuins and mono and pol-
y(ADP-ribose) polymerases (PARPs). These findings
suggest new chemical starting points for Nampt
inhibitors and further implicate this enzyme as a
target in cancer.
INTRODUCTION
CB30865 (Figure 1A) is a subnanomolar cytotoxic compound
discovered during the development of thymidylate synthase
(TS) inhibitors as anticancer agents (Skelton et al., 1998, 1999).
Using a quinazoline-based structural core, a series of pyridine
containing compounds were synthesized (Skelton et al., 1998,
1999). Interestingly, although 2- and 4-pyridyl compounds ex-
hibited cytotoxic potency consistent with their in vitro TS inhibi-
tory activity, a 3-pyridyl analog, CB30865, was 100-fold more
cytotoxic than would be anticipated by its in vitro potency
(Skelton et al., 1998, 1999). A number of controls including the
lack of rescue of cytotoxicity by addition of exogenous deoxy-
thymidine indicated that CB30865 (Skelton et al., 1998, 1999)
and its later analogs (Bavetsias et al., 2002) were acting on an
additional target. In further protection studies CB30865 was
not sensitive to the addition of a panel of metabolites (e.g., hypo-Chemistry & Biology 17,xanthine, leucovorin, S-adenosine methionine, adenosine, gua-
nosine, inosine, deoxycoformycin, methionine, and glycine)
(Skelton et al., 1999). A COMPARE analysis of the cancer cell
line cytotoxicity profile of CB30865 did not identify similarity to
known antitumor agents, suggesting a novel mechanism of
action (Skelton et al., 1999). Comparative genomic hybridization
(Skelton et al., 1999) and comparative expressed sequence
hybridization (Lu et al., 2001) identified an amplification on
7q22 in a CB30865-resistant cell line (W1L2:R8650). Microarray
analysis implicated several candidate cDNAs in the region, but
target identification was not reported (Lu et al., 2001). Testing
a large panel of known chemotherapeutic agents for cross-resis-
tance on the W1L2:R8650 versus the parental line was not
insightful (Skelton et al., 1999). Thus, despite these efforts, the
target of CB30865 has gone undetermined since its original
description in 1998. In this work, we apply a chemical proteo-
mics approach to identify the target of CB30865 and confirm
its activity in both in vitro and mechanism-based cellular assays.
RESULTS
Chemical Compounds and Confirmation of Cytotoxicity
We synthesized amethylpiperazinyl derivative of CB30865, MPI-
0479626 (Figure 1A), reported to have better solubility than the
parent compound and to lack residual TS inhibition due to meth-
ylation of the 3-position of the quinazolinone ring (Bavetsias
et al., 2002; Jones et al., 1985). Comparable to reported results,
we found that MPI-0479626 was a potent cytotoxic compound,
with an average TC50 of 0.7 nM in HCT116 cells (Figure 1B and
Table 1). To serve as a negative control in subsequent experi-
ments, we synthesized the corresponding 2-pyridyl analog,
MPI-0482593 (Figure 1A). This compound was over 400-fold
less potent in HCT116 cells than its 3-pyridyl isomer (Figure 1B
and Table 1).
We next added a linker to enable affinity purification. Reported
SAR (Bavetsias et al., 2002) indicated that the 2-position of the
quinazolinone ring may be permissive to linker attachment.
Therefore, an alkylamine linker was added to the methylpipera-
zine moiety of 3- and 2-pyridyl compounds, to yield MPI-
0479883 and MPI-0482594, respectively (Figure 1A). MPI-
0479883 had nanomolar cytotoxicity, suggesting that the linker
did not severely compromise function (Table 1). Importantly,659–664, June 25, 2010 ª2010 Elsevier Ltd All rights reserved 659
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Figure 1. CB30865 Analogs Interact with Nampt
(A) Quinazolinone structures.
(B) Viability assay. Mean ATP levels of two replicates normalized to a vehicle
control are plotted with the standard deviation.
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CB30865 Is a Nampt Inhibitorthe relative cellular potencies between the 2- and 3-pyridyl
compounds were maintained on linker addition (Figure 1B and
Table 1).Small Molecule Affinity Purification
To identify candidate targets of CB30865, MPI-0479883 was
immobilized on beads and incubated with a cell extract in the
presence or absence of excess free compound as a competitor.
As seen in the SDS-PAGE gel, a single prominent protein of
55 kD was evident in the pull-down, but not with ethanolamine660 Chemistry & Biology 17, 659–664, June 25, 2010 ª2010 Elsevier(EA) conjugated control beads or in the presence of competitor
(Figure 2A).
We next analyzed the pull-downs by reversed-phase HPLC-
tandem mass spectrometry (LC-MS/MS). The most abun-
dant protein in the MPI-0479883 purification was Nampt
(EC2.4.2.12), a 55 kD protein, which was not identified in either
of the two negative controls (Figure 2B). Other associated
proteins were substantially less abundant than Nampt and,
with a few exceptions, were also present in the negative controls.
Together, these data suggested that MPI-0479883 specifically
interacted with Nampt.
Confirmation of the LC-MS/MS identification of Nampt as the
55 kD protein in MPI-0479883 pull-downs was done by immuno-
blotting for Nampt in aliquots of the same samples shown in
Figure 2A. A single band was present in the Nampt immunoblot
that migrated at55 kD (Figure 2C). Consistent with the MS and
SDS-PAGE results, this band was absent in the EA control and
competitor blocked pull-downs (Figure 2A).
To further address specificity, we compared the abundance of
Nampt in MPI-0479883 pull-downs in the presence or absence
of excess free 3- or 2-pyridyl competitors, (Figure 2D). The
SDS-PAGE gel showed that MPI-0479883, but not MPI-
0482594, effectively competed with immobilized MPI-0479883
for Nampt binding (Figure 2D). Consistent with the above,
LC-MS/MS analyses on these samples indicated that spectral
counts assigned to Nampt decreased by 86% with the 3-pyridyl
competitor but only by 17% with the 2-pyridyl competitor (data
not shown). Next, we compared the abundance of Nampt in
purifications carried out with the 3- and 2-pyridyl compounds,
MPI-0479883 and MPI-0482594, respectively. In these experi-
ments, compounds were coupled to beads at different concen-
trations. By both SDS-PAGE and immunoblotting, MPI-0479883
specifically associated with Nampt, even when coupled at low
densities (Figure 2E). In contrast, in MPI-0482594 pull-downs
very little Nampt was detected even at the highest coupling
density (Figure 2E). Together, these results are consistent with
the 2-pyridyl compound having a lower affinity for Nampt and
with the relative cellular potencies of CB30865 analogs.Inhibition of Nampt In Vitro
In the first step of converting nicotinamide (NAM) to NAD, Nampt
transfers a phosphoribosyl group from 5-phosphoribosyl-1-
pyrophosphate (PRPP) to NAM, generating nicotinamide mono-
nucleotide (NMN) (Rongvaux et al., 2002). To determine if
CB30865 analogs are catalytic inhibitors of Nampt, we devel-
oped an in vitro assay for Nampt activity (Figure 3A). We
observed dose-dependent inhibition with MPI-0479883 in this
in vitro reaction (Figure 3B). A counter assay that bypassed
Nampt and included NMN (shaded reactions, Figure 3A) con-
firmed that MPI-0479883 was exclusively inhibiting Nampt in
the in vitro assay (Figure 3B). The average IC50 values from two
experiments for MPI-0479626 and MPI-0479883 were 0.23 nM
and 0.17 nM, respectively (Table 1). The 2-pyridyl compounds
were significantly less potent Nampt inhibitors (Table 1), consis-
tent with their diminished cytotoxicity. Two Nampt inhibitors,
APO866 and GMX1778, have been or are currently in clinical
trials for cancer (Holen et al., 2008; Hovstadius et al., 2002;
Ravaud et al., 2005; von Heideman et al., 2009). As controls,Ltd All rights reserved
Table 1. Comparison of Nampt Inhibitor Potencies
Compound Nampt Inhibition (IC50, nM) HCT116 Cytotoxicity (TC50, nM) NAD Depletion (IC50, nM) PAR Inhibition (IC50, nM)
MPI-0479626 0.23 ± 0.12 0.68 ± 0.5 0.38 ± 0.08 0.08 ± 0.02
MPI-0479883 0.17 ± 0.03 19 ± 11 4.8 ± 3.4 1.8 ± 1.6
MPI-0482593 74 ± 2.1 280 ± 110 290 ± 68 47.0 ± 0.4
MPI-0482594 29 ± 2.8 >10,000 6200 ± 2000 3300 ± 1400
APO866 0.14 ± 0.04 1.4 ± 0.7 0.41 ± 0.30 0.38 ± 0.37
GMX1778 0.07 ± 0.03 2.3 ± 2.0 4.7 ± 3.4 0.77 ± 0.47
Shown are averages with the standard deviation from multiple independent experiments.
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CB30865 Is a Nampt InhibitorAPO866 and GMX1778 were tested in the in vitro assay and both
potently inhibited Nampt activity (Table 1).
Cellular Assays of Nampt Inhibition
We next tested the CB30865 derivatives and the established
Nampt inhibitors in two cellular assays for Nampt activity.
In both assays, we tested for the ability of the observed cellular
effects to be prevented by exogenous nicotinic acid (NA), which
cells convert into NAD via Nampt-independent pathways. First,
we determined the levels of NAD-dependent PARP catalyzed
nuclear poly(ADP) ribose (PAR) deposition. In the absence of
a Nampt inhibitor, PAR was visible in the nucleus after exposure
to the PARP activator H2O2 (Figure 3C). Addition of MPI-0479883
prevented the accumulation of nuclear PAR in the presence ofA BMPI-
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Chemistry & Biology 17,H2O2 (Figure 3C). Quantification of the PAR signals from cells
treated with different concentrations of MPI-0479883 revealed
a dose-dependent decrease in nuclear PAR in response to
MPI-0479883 that was prevented by addition of NA (Figure 3D).
As a second measure of Nampt cellular activity, we measured
cellular NAD levels after a 24 hr incubation with Nampt inhibitors.
MPI-0479883 gave a dose-proportional decrease in cellular NAD
levels, whereas no decrease in NAD was seen in the presence of
NA (Figure 3E). Under these conditions, there was no appear-
ance of toxicity and no decrease in cellular ATP levels (data
not shown).
Last, to confirm the on-target cytotoxicity of MPI-0479883
suggested by the mechanism based cellular assays, we tested
if addition of NAwas sufficient to prevent cytotoxicity associatedRuby
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Figure 2. MPI-0479883 Interacts with Nampt
(A) MPI-0479883 affinity purification. SDS-PAGE gel
showing pull-downs with EA- or MPI-0479883-beads in
the presence (+) or absence () of 10 mM uncoupled
MPI-0479883 (Block).
(B) LC-MS/MS analysis of pull-downs. The heat map
indicates the total number of spectra corresponding to
the listed proteins.
(C) a-Nampt immunoblot of pull-downs. Lanes are the
same as in (A).
(D) Ruby-stained gel showing MPI-0479883 pull-downs
blocked with vehicle (), free MPI-0479883 (3p), or MPI-
0482594 (2p).
(E) Ruby-stained gel and a-Nampt immunoblot of pull-
downs done with MPI-0479883 or MPI-0482594 in the
presence (+) or absence () of 10 mM of their respective
free compound (Block). Density of compound was varied
by coupling at the concentrations indicated.
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Figure 3. MPI-0479883 Inhibits Nampt Activity In Vitro and In Vivo
(A) Schematic of the in vitro Nampt assay.
(B) Dose response of MPI-0479883 in the Nampt assay. Graphs indicate average Nampt activity (resorufin fluorescence) normalized to a vehicle control.
The standard deviation between duplicate samples is shown.
(C) PAR immunofluorescence assay. Cells treatedwith vehicle orMPI-0479883 andH2O2where indicatedwere stainedwith a-PAR antibody andHoechst tomark
nuclei.
(D) The PAR intensity for cells treated with MPI-0479883 in the presence or absence of NA was quantified and the mean from duplicate experiments plotted with
the standard deviation.
(E) NAD levels in cells treated with indicated amounts of MPI-0479883 in the presence (NA) or absence (vehicle) of 10 mM nicotinic acid. The mean and the stan-
dard error are shown.
(F) Cytotoxicity ofMPI-0479883 in the absence (vehicle) or presence (NA) of 10 mMnicotinic acid. Mean ATP levels of two replicates normalized to a vehicle control
are plotted with the standard deviation.
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CB30865 Is a Nampt Inhibitorwith Nampt inhibition. Indeed, cells given 10 mM NA retained
viability in the presence ofMPI-0479883, whereas in the absence
of NA there was a dose-dependent loss of HCT116 cell viability
(Figure 3F). It should be noted that in control experiments using
a panel of cytotoxic agents, NA did not generally prevent cyto-
toxicity (data not shown). Together these results suggest that
cytotoxicity of CB30865 is due to reduction in NAD through
Nampt inhibition.
DISCUSSION
We describe the identification of the cellular target of CB30865,
a highly potent cytotoxic orphan compound. Using small mole-
cule affinity purification, only one protein, of approximately
55 kD, strongly and specifically interacted with MPI-0479883,
a CB30865 analog. The LC-MS/MS analysis of the pull-down
suggested the 55 kD protein was Nampt. The proteomic identi-662 Chemistry & Biology 17, 659–664, June 25, 2010 ª2010 Elsevierfication and specificity were further confirmed by immunoblot-
ting pulldowns from 2- and 3-pyridyl isomers with a Nampt
specific antibody.
After confirming the Nampt interaction, CB30865 analogs
were shown to be potent inhibitors of Nampt activity in vitro
and in mechanism-based cellular assays. TC50 values for cyto-
toxicity, the two cellular assays and in vitro potency can be com-
pared in Table 1. Without exception, cytotoxicity and in vivo
Nampt inhibition were completely blocked by NA (Figure 3 and
data not shown). MPI-0479626 seems to be the most potent
inhibitor of Nampt in cells, with subnanomolar cellular TC50
values. The addition of an ionizable amine linker to both 2- and
3-pyridyl compounds had little effect on in vitro potency, but
diminished cellular potency, presumably due to effects on
permeability. The published SAR (Skelton et al., 1998, 1999)
for 3-pyridyl versus 2-pyridyl CB30865 analogs was in agree-
ment with the relative potencies in all assays.Ltd All rights reserved
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CB30865 Is a Nampt InhibitorThese consistencies in SAR and the complete prevention of
cellular effects with NA strongly support Nampt inhibition as
the molecular mechanism of cell killing for CB30865 and its
analogs. It should be noted that the nampt gene is located
in 7q22, the region amplified in the CB30865-resistant cell
line, and evidence exists that increased levels of Nampt can
render cells less sensitive to Nampt inhibition (Watson et al.,
2009).
A common structural feature of Nampt inhibitors is the pres-
ence of a pyridine ring. In a Nampt cocrystal structure, the pyridyl
moiety in APO866 has been shown to stack between the
aromatic rings of Phe193 and Tyr18, functionally substituting
for the pyridine ring present in the substrate, NAM, and product,
NMN, of the enzymatic reaction (Khan et al., 2006; Kang et al.,
2009). Molecular modeling based on the APO866-Nampt struc-
ture suggests that the pyridine in CB30865 can similarly stack
(unpublished data), thus allowing the CB30865 derivatives to
inhibit Nampt.
SIGNIFICANCE
We combined chemical proteomics with biochemical and
cellular pharmacological approaches to unambiguously
identify the target of an orphan molecule. The success of
this approach suggests it will be applicable for target identi-
fication of other molecules with unknown mechanism of
action. An activity responsible for conversion of NAM to
NAD was described decades ago (Preiss and Handler,
1957), but it was not until 1994 that human namptwas cloned
as a presumed cytokine called PBEF (Samal et al., 1994).
That PBEF was Nampt became apparent with the cloning
of a homologous gene in Haemophilus ducreyi that con-
ferred NAD independence (Martin et al., 2001). Nampt
activity was then confirmed for PBEF (Rongvaux et al.,
2002). Consequently, only recently have the diverse biolog-
ical functions of Nampt started to unfold (Gallı´ et al., 2010)
and CB30865 analogs should become valuable tools in this
regard. Concerning the clinical significance of these find-
ings, there are currently twoNampt inhibitors in clinical trials
in cancer (Holen et al., 2008; Hovstadius et al., 2002; Ravaud
et al., 2005; von Heideman et al., 2009) and Nampt has been
implicated in therapeutic areas outside of cancer as well
(recently reviewed in Gallı´ et al., 2010; Borradaile and Picker-
ing, 2009; Imai, 2009). The quinazolinone core of CB30865-
like molecules, which is unique among Nampt inhibitors,
may suggest new chemical starting points for future Nampt
drug discovery efforts.
EXPERIMENTAL PROCEDURES
Chemical Syntheses
All compounds were synthesized with commercially available starting mate-
rials. See Supplemental Experimental Procedures (available online) for details.
Cytotoxicity Assay
HCT116 cells (ATCC) were seeded at 5000 cells per well in 96-well plates. Indi-
cated amounts of compound and 10 mMNA, where applicable, were added to
cells for 72 hr. Viability was measured with the CellTiter-Glo Luminescent Cell
Viability Assay (Promega) according to manufacturer’s instructions. Lumines-
cence was measured using a TopCount NXT plate reader (Perkin-Elmer).Chemistry & Biology 17,Small Molecule Affinity Purification
Compounds containing an ethylamine linker were immobilized on beads and
incubated with cell lysates (see Supplemental Experimental Procedures).
Where indicated, excess free compound was added to the lysates before add-
ing the immobilized compound. Interacting proteins were pulled down and
analyzed by SDS-PAGE and LC-MS/MS.
Liquid Chromatography–Mass Spectrometry
Proteins were reduced, alkylated, and digested with trypsin directly on the
beads. Tryptic peptides were separated by nano-flow microcapillary
reversed-phased HPLC and eluted directly into an LTQ-Orbitrap (Thermo
Fisher). For each full scan the top five most abundant ions were fragmented.
Peptides and proteins were identified with Sequest (Eng et al., 1994) and hier-
archical clustering was done using BIGCAT (McAfee et al., 2006). See Supple-
mental Experimental Procedures for details.
Nampt Assay
PRPP, ATP, NAM, NMN, Triton X-100, UDP-glucose, and diaphorase were
purchased from Sigma. Human nampt, NMN adenylyltransferase (nmnat1),
and UDP-glucose dehydrogenase (ugdh) genes were inserted into a house-
modified Escherichia coli expression vector with an N-terminal 6xHis tag.
Protein expression in BL21-AI E. coli (Invitrogen) was induced by 0.2% L-arab-
inose and 0.5 mM IPTG at 30C. Proteins were purified on Ni-NTA resin
(QIAGEN), according to manufacturer’s instructions.
The Nampt assay was run in real-time mode in 96-well plates using 50 mM
Tris-HCl, pH 7.5, 1% DMSO (v/v), 0.01% Triton X-100 (v/v), 10 mM MgCl2,
2 mM ATP, 3 mM NAM, 8 mM PRPP, 50 pM Nampt, 5 nM Nmnat, 200 nM
Ugdh, 200 mM UDP-glucose, 0.02 U/ml diaphorase, and 0.25 mM resazurin.
Reactions were incubated at room temperature for up to 3 hr and then fluores-
cence at excitation and emission wavelengths of 510 nm and 590 nm, respec-
tively, was measured using a Gemini XS plate reader (Molecular Devices). The
counter assay was run as above, but with 1 mM NMN substituting for Nampt.
PAR Assay
MCF-10A cells (ATCC) stably transduced with the oncogene encoding PIK3-
CA(H1047R) were seeded at 6000 cells/well in 96-well plates. Compound
was added for 20–24 hr. Hydrogen peroxide (500 mM) was added for 8 min
and cells were fixed in 100% 20C methanol. After washing with PBS, cells
were incubated in blocking buffer (HBSS, 1% BSA, 0.1% Tween20) then
stained with an a-PAR mouse monoclonal antibody (Trevigen, 1:2000). For
detection, 1:1000 of a-mouse-Alexa488 and 5 mg/mL Hoechst 33342 were
used (Invitrogen). Images were acquired on a Pathway 855 (BD Biosciences)
using a 103 objective. Using Attovision software (BD Biosciences), the
Hoechst signal was used to segment nuclei and the PAR signal for each
nucleus in a well was subsequently averaged to generate a single value.
Assay to Measure NAD in Cellular Lysates
MCF-10A cells stably transduced with the oncogene encoding PIK3-
CA(H1047R) were treated with compound for 20–24 hr. Cells were washed
in PBS, lysed in 25 ml 0.5 M perchloric acid, and neutralized with 8 ml of 2 M
KOH/0.2 M K2HPO4. After clearing the precipitate by centrifugation, 10 ml
lysate was added to 90 ml of reaction (final concentration of 120 mM Tris-
HCl, pH 7.5, 0.01% Triton X-100, 35 mM UDP-Glucose, 50 nM Ugdh, 0.5 mM
resazurin, and 0.1 unit/mL diaphorase) for 1 hr at room temperature. Fluores-
cence was read as for Nampt inhibition.
SUPPLEMENTAL INFORMATION
Supplemental information includes Supplemental Experimental Proce-
dures and can be found with this article online at doi:10.1016/j.chembiol.
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